SAN DIEGO, Jan. 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), () today announced that its research and development team at its NexMed, USA, Inc. ("NexMed, USA") ...
SAN DIEGO, June 1, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), today announced that it has produced a series of online videos on the Company's NexACT® drug ...
SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT ® drug delivery technology ...
SAN DIEGO--(BUSINESS WIRE)-- NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT ® technology, today announced data from a pre-clinical study examining the ...
San Diego--(BUSINESS WIRE)-- NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) ...
Apricus has incorporated NexACT technology in therapies indicated for a wide range of indications and across different classes of drugs. The company's most advanced enhancer, NexACT-88, is used in ...
What it does: Develops new formulations of government-approved drugs using its patented NexACT molecules, which loosen so-called tight junctions that bind skin cells to each other, creating space for ...
Apricus Biosciences, Inc. announced the receipt of its latest issued Canadian patent, No. 2,512,015, entitled, “Topical Stabilized Prostaglandin E Compound Dosage Forms.” The patent covers a form of ...
Robbinsville, NJ, May 23, 2005--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal treatments based on its proprietary NexACT® drug delivery technology, today announced the preliminary ...
SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT ® technology, today announced the appointments of Jack A. Reynolds, Ph.D and ...
Pursuant to the MOU, PII will promote the NexACT technology to its clients and may independently identify new product development opportunities for this collaboration with NexMed. PII will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results